AEGiS-14IAC: Characteristics for demand and prescription of non occupational post exposure prophylaxis (NONOPEP) for HIV in Europe.

14th International AIDS Conference


Barcelona, Spain - July 7-12, 2002

DonateNow
Print this article

Characteristics for demand and prescription of non occupational post exposure prophylaxis (NONOPEP) for HIV in Europe.

Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. MoOrD1108)

Simon BG, Almeda J, Casabona J, Rey D, Puro V, Van Den Hoek A, Bernasconi E, Bergin C, Evans B, Lazanas M, Marcus U, Mota Miranda A, Tomazic J, rard M
CEESCAT, Hospital Universitai Germans Trias i Pujol, Badalona, Spain

BACKGROUND: Although there are no efficacy data on non-occupational post-exposure prophylaxis (NONOPEP), it is widely used. Following USA and Australia initiatives, an European Registry (European Commission, DGHCP) was implemented in April 2001 in 14 countries, to assess the feasibility, and eventually the effectiveness of NONOPEP. Our objectives are to describe the characteristics of the exposed individuals (EI), types of exposures, risk assessment and type of antiretroviral treatment(ART) prescribed, tolerance and adherence.

METHODS: EI who consult after a non occupational exposure to HIV, regardless of ART prescription, are prospectively recruited in the registry. Epidemiological, clinical and biological data are collected at the initial consultation, at 1 month and at 6 months follow up.

RESULTS: As of 31/12/2001, 408 cases were collected: 233(57.1%) sexual, 126(30.9%) parenteral, and 43(13.52%) other types of exposures. 68% of cases were men, and median age 30 years. The median time between exposure and the first consultation was 21 hours. In 79,4% of cases, source HIV status was unknown. In 318 cases, a risk assessment was documented by the physicians with 56(17,6 %) cases considered high, 106(33.3%) medium and 156(49.1%) low risk exposures. 59.3% of EI received ART, 26.5% for low risk exposures. ART included: 3 drugs in 80%, 2 drugs in 12.7% and 4 drugs in 7.2%. The follow up at 1 month was 61%, and 21.5% at 6 month. 50% of EI complained of side effects, only 12% discontinued their treatment. No HIV seroconversion so far.

CONCLUSIONS: NONOPEP is widely used in Europe. Sexual exposure is the main reason for consultation, being in most of the cases of low risk. Moreover, an important percentage of those received treatment. Data confirm the need to standardize recommendations of NONOPEP and to increase the awareness of their potential side effects. Although follow up at 6 months is difficult, NONOPEP registries are a good tool to monitor this practice.

Keywords: AEGIS, HIV Infections, HIV Seropositivity, Prescriptions, Drug, Europe, Occupational Exposure, Drug Therapy, Combination, Risk Assessment, Australia, Human, Male, prevention & control, Economics, therapy, drug therapyKWDaegis,hivinfections,hivseropositivity,prescriptions,drug,europe,occupationalexposure,drugtherapy,combination,riskassessment,australia,human,male,prevention&control,economics,therapy,drugtherapy

020707
MoOrD1108

Copyright © 2002 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.